Daily Watch List: Waste Management, Inc., Renasant Corp. (NASDAQ:RNST), Sangamo Biosciences (NASDAQ:SGMO), Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ)

On 08 October, Pilgrim’s Pride Corporation (NASDAQ:PPC) shares advanced 4.70% and was closed at $20.48. PPC EPS growth in last 5 year was 27.30%. Pilgrim’s Pride Corporation (NASDAQ:PPC) year to date (YTD) performance is -26.01%.

Pilgrim’s Pride Corporation (NASDAQ:PPC) announced that it will host its third quarter 2015 earnings conference call and webcast on Thursday, October 29, 2015 at 7:00 a.m. MDT (9:00 a.m. EDT). Prepared remarks regarding the company’s financial and operational results will be followed by a question and answer period with Pilgrim’s executive management team.

Waste Management, Inc. (NYSE:WM) shares increased 2.18% in last trading session and ended the day at $52.95. WM Gross Margin is 44.00% and its has a return on assets of 4.70%. Waste Management, Inc. (NYSE:WM) quarterly performance is 11.75%.

Effective October 1, 2015, the Board of Directors of Waste Management, Inc. (NYSE:WM) elected Kathleen M. Mazzarella as a member of the Board. Additionally, Ms. Mazzarella was appointed to the Management Development & Compensation Committee and the Nominating & Governance Committee of the Board of Directors.

Renasant Corp. (NASDAQ:RNST) ended the last trading day at $34.54. Company weekly volatility is calculated as 2.37% and price to cash ratio as 8.97. Renasant Corp. (NASDAQ:RNST) showed a weekly performance of 5.08%.

Zacks cut shares of Renasant Corp. (NASDAQ:RNST)from a hold rating to a sell rating in a research report report published on Monday.

Sangamo Biosciences Inc. (NASDAQ:SGMO) shares moved down -2.46% in last trading session and ended the day at $5.56. Its has a return on assets of -12.20%. Sangamo Biosciences Inc. (NASDAQ:SGMO) quarterly performance is -43.61%.

Sangamo Biosciences Inc. (NASDAQ:SGMO), announced that Elizabeth Wolffe, Ph.D., Sangamo’s vice president of corporate communications, provide an update on the progress of Sangamo’s ZFP Therapeutic® development programs and an overview of the company’s business strategy at 2:30pm PT on Wednesday, October 7, 2015, at the 2015 Stem Cell Meeting on the Mesa. In addition, as the Chairman of the Alliance for Regenerative Medicine (ARM), Edward Lanphier, Sangamo’s president and chief executive officer, will open the meeting with a welcome address. The meeting will be held from October 7-9 in La Jolla, California.

Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) caters to the Healthcare space. It has a net profit margin of 20.80% and weekly performance is 0.44%. On the last day of trading company shares ended up at $133.03. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) distance from 50-day simple moving average (SMA50) is -19.25%.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted for filing with Priority Review its recently submitted New Drug Application (NDA) for defibrotide. Defibrotide is an investigational agent proposed for the treatment of patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with evidence of multi-organ dysfunction (MOD) following hematopoietic stem-cell transplantation (HSCT).